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Abstract
Introduction: Bisphosphonates consist of a range of drugs used in the treatment of osteopathy or 
some osteotropic malignancies. Medication-related osteonecrosis of the jaw (MRONJ) is a serious 
adverse consequence of their use. Conventional treatment is not always effective, so it is necessary to 
resort to the use of adjuvant therapies. This study aimed to evaluate the effectiveness of the association 
of surgery, antibiotic therapy and low-level laser (LLL) therapy as a treatment strategy for MRONJ 
through the presentation of a clinical case. 
Case Presentation: A 49-year-old female patient presented for the diagnosis and treatment of bone 
lesions in the maxillae. The patient reported that she had used zoledronate for 1 year. Five years 
later there were 2 painless bone lesions on both sides of the maxilla, following the extraction of the 
first upper molars. Clinical, tomographic and histopathologic examination established the diagnosis 
of MRONJ. The treatment consisted of the curettage of the necrotic bone, antibiotic and thirteen 
LLL therapy sessions. Integral mucosal healing was observed after a two-month follow-up and no 
symptoms were detected. The patient was evaluated at 6 and 12 postoperative months without 
complications. 
Conclusion: The combination of surgery, antibiotic therapy, and LLL therapy has shown to be effective 
in the treatment of MRONJ.
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Osteonecrosis. 
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Introduction
A serious adverse consequence of using some oral 
or intravenous antiresorptive and/or antiangiogenic 
agents is the medication-related osteonecrosis of the 
jaw (MRONJ).1 This condition is characterized by the 
presence of the exposed bone or the bone probed through 
an extraoral or intraoral fistula in the maxillofacial region 
for a period longer than 8 weeks in the patients who 
are submitted to previous or current medication with 
antiresorptive or antiangiogenic agents and do not have 
any previous history of radiotherapy or metastatic disease 
within the jaws.1
The American Association of Oral and Maxillofacial 
Surgeons (AAOMS) has classified MRONJ into three 
stages: I. The exposed necrotic bone with no signs of 
infection and pain (asymptomatic); II. The exposed 
necrotic bone with the signs of infection and pain 
(symptomatic); and III. The exposed, symptomatic 
and infected bone, associated with the presence of 
fistulas, maxillary sinus and/or pathological fractures.1 
Bisphosphonates (BPs) are among the primary agents that 
result in the occurrence of MRONJ. BPs are used within 
the current pharmacological arsenal against osteoclast-
mediated bone loss and for the treatment of some 
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osteoporotic conditions, hypercalcemia, Paget’s disease, 
and multiple myeloma and the control of malignancies.2 
Marx3 were the first to relate the use of BPs with the onset 
of MRONJ. MRONJ is less common in patients who use 
BPs orally; however, in patients who use long-term BPs, 
as zoledronate, via parenteral , prescribed for adjuvant 
oncologic therapy, MRONJ can affect 1% to 12% of 
patients.4 Since BPs have cumulative effect on mineralized 
tissues, this incidence may increase up to 21% after the 
third year of continuing therapy.4 
Although MRONJ has been described for more than a 
decade, its pathogenesis is still poorly understood, which 
hinders its prevention and treatment. In addition, there 
are not any established and definitive clinical protocols 
to be followed in the treatment of MRONJ. The currently 
proposed treatments are based on the clinical staging of 
the disease, ranging from mouthwash with chlorhexidine 
and antibiotics to debridement and surgical resection of 
the affected area.1 However, this therapeutic model has 
proven inadequate, and in some cases, recurrences are 
common, which shows that there is a tremendous need to 
involve other adjuvant therapies.
In vitro and in vivo studies have shown that BPs have 
negative effects on several cell lines and consequently 
compromise the ability of the tissue to perform repair.5-7 
Thus, the use of adjuvant therapies with biostimulatory 
effects could promote benefits, including the cases in 
which the standard protocol does not achieve satisfactory 
results. 
In this context, some studies have used platelet-rich 
plasma (PRP),8 hyperbaric oxygen,9 bone morphogenetic 
protein10 and low-level laser (LLL) as adjuvant therapies 
for the treatment of MRONJ.11,12 Interestingly, LLL 
therapy has shown promising results for the treatment of 
this condition.11-13
The basic mechanism underlying LLL therapy has not 
completely been elucidated yet. The primary reactions 
occur at the mitochondrial level, specifically in the 
electron transport chain, where irradiation promotes 
photoreceptors activation, which results in increased 
energy potential cells. Other reactions increase cell 
proliferation and cell differentiation when they occur, 
involving the transduction of signals to the cytoplasm 
level.14 
Previous animal studies by our research group15 and 
other research groups16-18 have shown that LLL therapy 
after extraction improves the alveolar repair process. 
Similarly, clinical studies have also indicated that LLL 
therapy has positive effects on the main signs and 
symptoms during the post-extraction wound healing 
process.12,19-21
In some clinical studies, Vescovi et al,12,22 showed a 
higher therapeutic success rate when LLL therapy was 
associated with conventional therapy in the treatment of 
MRONJ. Corroborating these findings, other literature 
reviews also report the benefits of the inclusion of LLL 
as a promising option for MRONJ management.23,24 
Therefore, this study aimed to evaluate the effect of the 
association of surgery intervention, antibiotic therapy, 
and LLL therapy, as a treatment strategy for MRONJ 
through the presentation of a case. 
Case Presentation
A 49-year-old female patient, who was a smoker, 
presented at the clinical division of School of Dentistry, 
Araçatuba, São Paulo State University (UNESP), Brazil 
for the diagnosis and treatment of 2 bone lesions located 
in the bilateral molar region of the maxilla. Initially, 
ethical considerations were given and written informed 
consent was obtained from the patient to be submitted 
to care and subsequent treatments. During anamnesis, 
the patient reported the use of zoledronate (zoledronic 
acid), 4 mg/month for 12 months for the treatment of an 
osteoblastoma in the ribs. Five years after stopping the use 
of this drug, the patient underwent the extraction of the 
first upper molars; however, after 6 months, the dental 
sockets showed no clinical signs of tissue repair. The 
patient reported the use of 1500 mg/d of amoxicillin for 
3 months. At the end of this period, as was found during 
a physical examination, an exposed bone was noted with 
painful symptoms and drainage of the purulent collection 
in the posterior region of both sides of the maxilla (Figure 
1A and 1B). Radiographic examination and a computed 
tomography (CT) scan of the patient exhibited, on 
both sides, an irregular lesion with ill-defined margins, 
radiolucent aspect, and alveolar bone resorption with 
maxillary sinus involvement (Figure 1C, 1D and 1E).
Based on the history, physical examination, 
radiography, and tomography, the diagnosis of MRONJ 
(stage III) was established and confirmed with a posterior 
histopathologic exam. The treatment consisted of surgical 
debridement therapy, antibiotic administration, and 
multiple LLL therapy sessions.
Surgical Procedures
The patient was submitted to all surgical procedures under 
local anesthesia. The detachment of the mucosa was held 
in the wound edges. The necrotic bone was removed by 
using a Dietrich forceps (Figure 2A and 2B). Then, the 
curettage of the necrotic bone was conducted until the 
bone walls were bleeding (Figure 2C). Bone defects were 
found to involve the maxillary sinus which was confirmed 
by the use of the Valsalva maneuver. A classic ball-shaped 
bur was used to perform the osteoplasty and to remove 
the sharp angles of the bone. Wounds were abundantly 
irrigated with a sterile saline physiologic solution and 
the first LLL therapy session was performed during the 
transoperative period (Figure 2D).
LLL therapy was performed with the use of a GaAlAs 
(gallium-aluminum arsenium) diode laser (Thera Lase®, 
D.M.C. Ltd, São Carlos, SP, Brazil) with a wavelength of 
808 nm and a spot size of 0.0283 cm2. LLL was performed 
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with an energy density of 19.43 J/cm2/point, 4.4 J of total 
energy, a power of 50 mW, a power density of 1.76 W/
cm2, and in a continuous mode. The laser was applied 
to 6 points on the wound edges and to 2 points in the 
center (Figure 2D) for 11 seconds for each dot, totaling 
88 seconds on each side and a cumulative dose of 155.44 
J/cm2. The first LLL therapy session was performed even 
before making the suture. After this, the sessions of LLL 
therapy were performed twice a week in the first month, 
followed by an LLL therapy session once a week in the 
second month. All necessary biosafety measures were 
employed during LLL therapy, including the disinfection 
of the laser tip and the use of protection eyeglasses by the 
patient and the operator.
A flap in the mucosa was performed and sutured in 
order to cover the defect and allow first intention healing. 
(Figure 2E and 2F). Antibiotic therapy with clindamycin 
(1200 mg/day) was administered for 14 days following the 
procedure.
Part of the necrotic bone was sent to the Pathology 
Laboratory of School of Dentistry, Araçatuba – UNESP 
for histopathologic examination. The histopathological 
analysis showed an extensive area of   necrotic bone 
tissue characterized by empty gaps of o steocytes and 
circumscribed by intense chronic inflammatory infiltrate 
and necrotic debris with microbial colonies of bacteria, 
which histopathologically proved the clinical hypothesis 
of MRONJ (Figure 3A, 3B and 3C). 
Figure 1. Clinical and Imaging Characteristics of the Lesion in the 
Preoperative Period. (A-B) Clinical aspects of the right (A) and left 
(B) maxillary lesions. (C-E) Radiographic (C) and tomographic (D-E) 
appearance.
Figure 2. Surgical Transoperative. (A) shows the removal of the bone 
sequestration, which is evidenced in (B). In (C), the lesion located in the 
maxilla can be observed at the end of the surgery. (D) shows an injury 
located in the maxilla soon after the surgery had been completed and a 
laser tip positioned at a point of irradiation. (E) and (F) show the aspect of 
the surgical sites after the suture.
Figure 3. Histopathological Characteristics of the Lesion. (A - C) 
Photomicrographs evidencing the histological aspect of the bone 
sequestration. Note the non-vital bone tissue and marrow spaces filled 
with necrotic cell remnants, inflammatory infiltrate and bacterial colonies. 
Abbreviations and symbols: asterisks, necrotic remains, and bacterial 
colonies; Arrows, empty gaps; nb, necrotic bone. Scale bar: 400 µm (A), 
100 µm (B), 40 µm (C). Staining: Hematoxylin and Eosin. 
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During the laser treatment, the patient was monitored 
weekly and radiographic and tomographic exams were 
done after 12 postoperative months. Follow-up in the 
periods of 3, 6 (Figure 4A, 4B and 4C) and 12 postoperative 
months showed that the lesion area completely recovered 
with healthy mucosa covering the neoformed bone 
(Figure 4D and 4E).
Discussion
MRONJ has become a major concern in dentistry due to the 
difficulty in obtaining a cure, substantially compromising 
the life quality of the patients. According to Ruggiero and 
Woo,25 BPs have a half-life of about 10 years. We observed 
the development of MRONJ 5 years after the completion 
of treatment with zoledronic acid. In an epidemiological 
study, Otto et al26 identified the main risk factors for the 
development of MRONJ. According to this study, the 
patient had all the risk factors for developing the disease, 
such as advanced age, female gender, smoker, chronic 
intravenous use of zoledronate (a nitrogen BPs) and the 
fact that she had been subjected to an invasive surgery as 
a tooth extraction.26,27 The complication associated with 
this case is the fact that the patient presents a maxillary 
sinus involvement, representing MRONJ in stage III. 
The results from a study by Berrone et al28 showed that 
the treatment of 5 patients with MRONJ in stage III with 
surgical debridement, antibiotics and closing of wounds 
using the buccal fat pad for bone coverage was successful. 
There was no recurrence during a twelve-month 
follow-up. The authors reported successful treatment, 
supposedly stimulated by the rich blood supply to the 
area.28 The increased prevalence of MRONJ is in the jaw, 
in particular in the premolar and molar regions, and it 
is attributed to the lower blood supply to the bone tissue 
of this area, which makes the strategies for increasing the 
vascularization necessary.
Ristow and Pauke29 defined as successful surgical 
therapy for MRONJ when all necrotic bone tissue has 
been removed, there is completely repair and recoating of 
the overlying mucosa and no symptoms are reported for 
at least 4 weeks after the surgical procedure. According 
to AAOMS, a recommended treatment should be the 
limitation of infection, the relief of pain symptoms, 
and the control of the necrosis progression.1 Antibiotic 
therapy and a surgical procedure may not be sufficient to 
cure MRONJ in some cases,30 so we choose to associate it 
with adjuvant therapy. LLL therapy, which is also called 
photobiomodulation, has properties that could favor the 
process of tissue repair.15,31
LLL therapy is able to modulate the metabolism of 
human osteoblasts by increasing their proliferation and 
differentiation.32 Moreover, LLL therapy is claimed to 
have beneficial analgesic and anti-inflammatory effects.33 
It promotes bone formation and soft tissue healing and 
has important angiogenic properties for tissue repair.34 
Positive effects, which have been suggested and confirmed 
Figure 4. Clinical and Imaging Characteristics of the Lesion Site in the 
Postoperative Period (1 Year). (A-B) Clinical aspects of the posterior 
region of the right (A) and left (B) maxillae. (C-E) Radiographic (C) and 
tomographic (D-E) aspect of both sides of the maxilla.
with a meta-analysis, include an increase in collagen 
synthesis and tensile strength, accelerating the resolution 
of the inflammatory process and the diminution of 
healing time and wound size.35 
These facts could explain the beneficial effect of LLL 
therapy when it is associated with the conventional 
treatment of MRONJ.12,22 The laser parameters, including 
the energy that is delivered, power density, pulse duration, 
appropriate treatment, timing and repetition, and the 
appropriate anatomical location must be adequate to 
create a biostimulatory effect.23
In this case report, we used the laser emitting GaAlAs at 
a wavelength of 808 nm with an energy density of 19.4 J/
cm2/point (8 points) for a period of 2 months (13 sessions). 
Other protocols have been described for the treatment of 
MRONJ. Romeo et al36 used a double diode laser (GaAs) 
simultaneously emitting at 2 different wavelengths, 650 
nm and 904-910 nm. Vescovi et al37 applied a LLL therapy 
with previous irrigations with a 10% povidone iodine 
solution and an emitter Nd: YAG laser at a wavelength of 
1064 nm, power of 2.25 W and frequency of 15 Hz in a 
unfocused mode and 2 mm away from the tissues for 1 
minute (power density, 1562.5 W/cm2, fluence, 7 J/cm2) 5 
times repeatedly. Altay et al31 employed a GaAlAs device 
with a wavelength of 808 nm, power of 0.5 W, and an 
energy density of 5 J/cm2. With regard to the number and 
frequency of LLL therapy sessions, there was a variation 
in the studies from one37 to 5 sessions31 and from 65036 to 
1562.5 nm37 respectively. All of these protocols showed 
good results, as did this case report by improving tissue 
repair,31 complete mucosal healing in about 2 weeks37 and 
a reduction of pain.36 The number of irradiation protocol 
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variables in laser use, as well as the different affected 
areas and their intensity that occur with MRONJ, the 
different laser devices and wavelengths, and the difficulty 
in standardizing of the amount of energy used make it 
difficult to establish treatment protocols for the treatment 
of this pathological condition. Romeo et al36 encourage an 
individual protocol for each situation.
It has been recognized that Actinomyces play an 
important role in MRONJ pathophysiology, although its 
mechanism has not completely been elucidated yet.1 In 
this case, after extraction, the patient continued the use 
of 1500 mg of Amoxicillin per day for 3 months, which 
was not sufficient to prevent the necrosis progression. 
Martins et al38 associated surgical debridement, antibiotic 
therapy, LLL therapy to PRP in the treatment of MRONJ, 
achieving a better result when the combination of 
therapies was used. Perhaps the key to curing MRONJ 
was to control bacterial and remove the necrotic tissue, 
but above all to biostimulate the area, which was achieved 
by adjuvant therapy with LLL. However, more studies 
must be conducted to prove the beneficial effects of LLL 
therapy for the treatment of MRONJ.
Conclusion
Based on the results obtained from this clinical case 
report and considering its due limits, we concluded that 
the combination of surgery, antibiotic therapy, and LLL 
therapy was effective in the treatment of MRONJ, which 
is put forth as a promising option for adjunctive use in the 
treatment of this pathological condition.
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